0001179929-25-000128
SEC filingMolina Healthcare's Q3 2025 results were pressured by a challenging medical cost environment, with consolidated MCR rising 340 bps to 92.6%, leading to a 76% decline in net income.
Molina Healthcare reported Q3 2025 results that fell sharply year-over-year, primarily due to a challenging medical cost environment. Premium revenue increased 12% to $10.84 billion, driven by the February 2025 acquisition of ConnectiCare and rate increases across segments. However, medical care costs grew faster, rising 16% to $10.04 billion, resulting in a consolidated medical care ratio (MCR) of 92.6%, up 340 basis points from 89.2% in Q3 2024. The medical margin (premium revenue less medical costs) contracted 24% to $797 million. Lower investment income ($108M vs $118M) and higher interest expense ($49M vs $29M) further weighed on profitability. Operating income fell 71% to $137 million, and net income declined 76% to $79 million ($1.51 per diluted share) from $326 million ($5.65 per diluted share) in the prior-year quarter. The effective tax rate dropped to 10.1% from 25.7%, reflecting increased tax benefits from transferable federal tax credits.
For the nine months ended September 30, 2025, premium revenue rose 13% to $32.34 billion, but net income fell 32% to $632 million. The consolidated MCR for the nine-month period was 90.8%, up 200 basis points year-over-year, above the company's long-term target range.
Total assets at September 30, 2025 were $15.70 billion, relatively flat compared to $15.63 billion at December 31, 2024. Cash and cash equivalents declined to $4.22 billion from $4.66 billion, while investments decreased slightly to $4.23 billion. Current assets totaled $12.55 billion, down from $12.77 billion. On the liability side, medical claims and benefits payable rose to $4.84 billion from $4.64 billion. Long-term debt increased significantly to $3.66 billion from $2.92 billion, reflecting $1.1 billion in new borrowings under the credit facility and term loans during the period. Stockholders' equity decreased to $4.19 billion from $4.50 billion, driven by $1.0 billion in common stock repurchases and $18 million in stock repurchase excise taxes, partially offset by net income and other comprehensive income.
The parent company held $108 million in cash and investments at quarter-end, down from $445 million at year-end 2024, largely due to share repurchases and the ConnectiCare acquisition. Dividends from regulated subsidiaries totaled $648 million in the first nine months of 2025. Working capital was $5.1 billion, compared to $4.9 billion at year-end 2024.
Operating cash flow was negative $237 million for the nine months ended September 30, 2025, versus positive $868 million in the same period of 2024. The decline was primarily due to timing differences in settlements with government agencies, including Medicaid minimum MLR and medical cost corridor payments, Marketplace risk adjustment payables, and tax payments. Net cash provided by investing activities was $82 million, compared to $483 million used in the prior year, reflecting net proceeds from investment sales. Financing activities used $262 million, driven by $1.0 billion in common stock repurchases, offset by $1.1 billion in new borrowings. Capital expenditures were $102 million, up from $89 million. The company maintains significant liquidity with $8.7 billion in cash and investments at the consolidated level.
Management attributed the elevated MCR to broad-based medical cost pressure across all segments. In Medicaid, higher-than-expected costs from acuity shifts, product mix changes, and increased utilization in behavioral health, high-cost drugs, long-term services, and inpatient/outpatient settings offset premium rate increases. The Medicaid MCR of 92.0% was above the long-term target. Medicare MCR rose to 93.6%, driven by high-acuity duals populations and costs for LTSS and pharmacy drugs, partially offset by benefit adjustments and exit from MAPD in 13 states. Marketplace MCR surged to 95.6% as utilization outpaced risk adjustment revenues, and initial MCRs from ConnectiCare added pressure.
On the regulatory front, the One Big Beautiful Bill Act (OBBBA) signed in July 2025 includes Medicaid work requirements, more frequent redeterminations, and cost sharing for Expansion populations, expected to reduce enrollment by 15-20% on 1.3 million members. The company also faces changes to Marketplace program integrity and affordability rules, which may reduce enrollment. Management noted that premium rate increases are being implemented to address cost trends but have not yet fully caught up.
G&A expense ratio improved to 6.4% in Q3 2025 from 6.5% a year earlier, reflecting cost discipline and operating leverage. Interest expense increased due to new debt issued in 2025 and the November 2024 6.250% notes.
The company continues to invest in growth through contract wins (Mississippi, Nevada, Florida, Wisconsin) and the ConnectiCare acquisition. Share repurchase activity remained significant, with $1 billion in buybacks during the first nine months and $500 million remaining under the April 2025 authorization.
Segment performance was mixed. Medicaid premium revenue grew 5% but medical margin declined 12% to $639 million due to a 150 bps MCR increase. Medicare premium revenue rose 18% but medical margin fell 27% to $103 million as MCR increased 400 bps. Marketplace premium revenue more than doubled, but medical margin dropped 70% to $53 million as MCR soared 2,260 bps. Prior year reserve development was favorable by $124 million in the nine months ended September 30, 2025, compared to $625 million in the prior year, driven by lower-than-expected costs in Medicaid and Medicare, partially offset by higher costs in Marketplace.
The ConnectiCare acquisition contributed approximately 140,000 members and added $350 million in goodwill. The valuation is still provisional. Goodwill and intangible assets, net, increased to $2.20 billion from $1.94 billion at year-end 2024.
The company's debt structure includes $800 million 4.375% notes due 2028, $650 million 3.875% notes due 2030, $750 million 3.875% notes due 2032, $750 million 6.250% notes due 2033, and $740 million in term loans. As of September 30, 2025, no amounts were outstanding under the $1.25 billion revolving credit facility. The company was in compliance with all covenants.
Stock-based compensation was $27 million for the nine months, down from $98 million in the prior year.